Insulet Announces New Organizational Structure to Drive Further Growth

Insulet Corporation  the global leader in tubeless insulin pump technology with its Omnipod brand of products, announced its new organizational structure designed to accelerate innovation and commercialization. The new structure will be implemented during the second half of this year with new leadership roles effective July 1, 2023. The leadership team will continue to report to Jim Hollingshead, President and Chief Executive Officer.

Latest Insights: Embrace AI to become a W.I.T.C.H. Leader

“He helped build a deep, talented commercial team that has contributed to our strong customer base growth, an exceptional customer experience, and differentiated business model and pharmacy channel access. All of us at Insulet wish Bret well in his next endeavor.”

Mr. Hollingshead said, “It is an exciting time at Insulet as we continue to advance our mission to improve the lives of people with diabetes. Our Company has achieved remarkable growth, recently accelerated by the U.S. commercial launch of our revolutionary Omnipod 5 Automated Insulin Delivery System, which we will soon launch internationally. The global markets and customers we serve have also rapidly evolved. Now is the ideal time to realign our organizational structure to support our strong momentum, accelerate our robust innovation pipeline, and drive continued global expansion. Our new organizational design creates a more focused and specialized structure that strengthens our commercial capabilities and fosters further innovation and cross-functional collaboration.”

As part of the new organizational structure, we have created the following roles, effective July 1, 2023:

• Eric Benjamin has been named Chief Product & Customer Experience Officer (CPXO), responsible for product vision and execution, including franchise management and global growth strategies, product and portfolio management, and driving the end-to-end customer experience across the enterprise.
• Mark Field has been named Chief Technology Officer, responsible for software and hardware engineering, information technology, cyber security, digital and data services, and system architecture. Mr. Field will be responsible for ensuring that we continue to have robust software platforms, modules, and other technology capabilities to support Insulet’s strategy and goals.
• The previous role of Chief Commercial Officer has been separated into two leadership positions in order to drive more focused regional and local market execution.
  • The Company has commenced a search for a U.S. General Manager, who will focus on accelerating our U.S. commercial growth, go-to-market strategies, and sales operations. This newly created role will also drive enhanced and consistent global commercial capabilities across the enterprise.
  • Patrick Crannell will continue in his role as International General Manager overseeing the Company’s international commercial operations. He is responsible for leading go-to-market execution and expansion in international markets, as well as the strategic, commercial, operational, and financial performance of the international operations. Mr. Crannell will now report directly to the CEO.

Recommended: Enhancing AI: Why New Technology Must Include Diversity

“Bret has played an integral role in the commercial successes of the Company over the last six years, most recently with the U.S. commercial launch of Omnipod 5 and the continued global expansion of Omnipod DASH,” said Mr. Hollingshead. “He helped build a deep, talented commercial team that has contributed to our strong customer base growth, an exceptional customer experience, and differentiated business model and pharmacy channel access. All of us at Insulet wish Bret well in his next endeavor.”

Mr. Hollingshead continued, “Consumer-focused innovation is central to everything we do. As our business becomes larger and more complex, we have structured our operations and leadership to more efficiently and effectively drive and scale our innovations and support our commercial and operational priorities. With the changes announced today, Insulet is better positioned to continue driving customer adoption, international expansion, and enhanced customer experience as we support hundreds of thousands of people with diabetes across the globe.”

Latest Insights: Synthetic Data: A Game-Changer for Marketers or Just Another Fad?

[To share your insights with us, please write to sghosh@martechseries.com]